Wall Street brokerages forecast that United Therapeutics Co. (NASDAQ:UTHR) will report earnings of $3.52 per share for the current quarter, Zacks Investment Research reports. Six analysts have made estimates for United Therapeutics’ earnings. The lowest EPS estimate is $1.48 and the highest is $4.87. United Therapeutics posted earnings per share of $2.43 in the same quarter last year, which suggests a positive year-over-year growth rate of 44.9%. The company is expected to report its next quarterly earnings report on Wednesday, February 28th.
On average, analysts expect that United Therapeutics will report full-year earnings of $12.45 per share for the current year, with EPS estimates ranging from $10.39 to $13.72. For the next year, analysts anticipate that the business will post earnings of $11.62 per share, with EPS estimates ranging from $10.73 to $12.32. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of analysts that that provide coverage for United Therapeutics.
United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, October 25th. The biotechnology company reported $6.27 earnings per share for the quarter, topping analysts’ consensus estimates of $4.01 by $2.26. The business had revenue of $445.50 million for the quarter, compared to analyst estimates of $426.43 million. United Therapeutics had a return on equity of 26.24% and a net margin of 30.50%. The company’s quarterly revenue was up 9.1% compared to the same quarter last year. During the same period in the prior year, the company earned $4.23 EPS.
A number of brokerages have weighed in on UTHR. TheStreet lowered United Therapeutics from a “b-” rating to a “c” rating in a research note on Friday, September 29th. Oppenheimer reiterated a “buy” rating on shares of United Therapeutics in a research report on Friday, September 8th. ValuEngine upgraded United Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, November 30th. BidaskClub upgraded United Therapeutics from a “sell” rating to a “hold” rating in a research report on Wednesday, December 6th. Finally, Cowen reiterated a “hold” rating and set a $129.00 price objective on shares of United Therapeutics in a research report on Friday, October 27th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating and three have assigned a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus price target of $136.10.
In related news, CEO Martine A. Rothblatt sold 1,274 shares of the firm’s stock in a transaction that occurred on Thursday, September 21st. The stock was sold at an average price of $116.07, for a total transaction of $147,873.18. Following the transaction, the chief executive officer now directly owns 2,343 shares in the company, valued at approximately $271,952.01. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Martine A. Rothblatt sold 1,258 shares of the firm’s stock in a transaction that occurred on Thursday, September 14th. The stock was sold at an average price of $122.08, for a total value of $153,576.64. Following the transaction, the chief executive officer now owns 2,327 shares in the company, valued at $284,080.16. The disclosure for this sale can be found here. Insiders have sold a total of 22,668 shares of company stock worth $2,755,406 over the last quarter. Corporate insiders own 7.80% of the company’s stock.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. BlackRock Inc. lifted its holdings in United Therapeutics by 3.3% in the 2nd quarter. BlackRock Inc. now owns 4,897,334 shares of the biotechnology company’s stock worth $635,330,000 after buying an additional 155,349 shares during the period. FMR LLC lifted its holdings in United Therapeutics by 2.8% in the 2nd quarter. FMR LLC now owns 4,254,841 shares of the biotechnology company’s stock worth $551,980,000 after buying an additional 116,062 shares during the period. Vanguard Group Inc. lifted its holdings in United Therapeutics by 0.7% in the 2nd quarter. Vanguard Group Inc. now owns 3,810,146 shares of the biotechnology company’s stock worth $494,291,000 after buying an additional 25,047 shares during the period. State Street Corp lifted its holdings in United Therapeutics by 0.9% in the 2nd quarter. State Street Corp now owns 2,014,506 shares of the biotechnology company’s stock worth $261,345,000 after buying an additional 17,179 shares during the period. Finally, Schroder Investment Management Group lifted its holdings in United Therapeutics by 42.8% in the 2nd quarter. Schroder Investment Management Group now owns 1,091,675 shares of the biotechnology company’s stock worth $143,359,000 after buying an additional 327,360 shares during the period. Institutional investors and hedge funds own 99.94% of the company’s stock.
United Therapeutics (NASDAQ UTHR) opened at $136.21 on Monday. The firm has a market capitalization of $5,890.00, a PE ratio of 12.01 and a beta of 1.42. United Therapeutics has a one year low of $112.01 and a one year high of $169.89.
COPYRIGHT VIOLATION NOTICE: This article was reported by TrueBlueTribune and is owned by of TrueBlueTribune. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright & trademark legislation. The legal version of this article can be accessed at https://www.truebluetribune.com/2018/01/03/united-therapeutics-co-uthr-expected-to-post-earnings-of-3-52-per-share.html.
About United Therapeutics
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related companies with MarketBeat.com's FREE daily email newsletter.